Ubrogepant

Ubrogepant
Clinical data
Trade names	Ubrelvy
Other names	MK-1602
AHFS/Drugs.com	Monograph
MedlinePlus	a620016
License data	US DailyMed: Ubrogepant;
Routes of; administration	By mouth
ATC code	N02CD04 (WHO) ;
Legal status
Legal status	CA: ℞-only; US: ℞-only;
Pharmacokinetic data
Protein binding	87% (in vitro)
Elimination half-life	5-7 hrs
Excretion	fecal/biliary
Identifiers
	IUPAC name (6S)-N-[(3S,5S,6R)-6-Methyl-2-oxo-5-phenyl-1-(2,2,2-trifluoroethyl)-3-piperidinyl]-2'-oxo-1',2',5,7-tetrahydrospiro[cyclopenta[b]pyridine-6,3'-pyrrolo[2,3-b]pyridine]-3-carboxamide;
CAS Number	1374248-77-7;
PubChem CID	68748835;
DrugBank	DB15328;
ChemSpider	28536135;
UNII	AD0O8X2QJR;
KEGG	D10673;
ChEMBL	ChEMBL2364638;
CompTox Dashboard (EPA)	DTXSID00160178 ;
Chemical and physical data
Formula	C29H26F3N5O3
Molar mass	549.554 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F;
	InChI InChI=1S/C29H26F3N5O3/c1-16-20(17-6-3-2-4-7-17)11-22(26(39)37(16)15-29(30,31)32)35-25(38)19-10-18-12-28(13-23(18)34-14-19)21-8-5-9-33-24(21)36-27(28)40/h2-10,14,16,20,22H,11-13,15H2,1H3,(H,35,38)(H,33,36,40)/t16-,20-,22+,28+/m1/s1; Key:DDOOFTLHJSMHLN-ZQHRPCGSSA-N;

Ubrogepant, sold under the brand name Ubrelvy, is a medication used for the acute (immediate) treatment of migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. It is not indicated for the preventive treatment of migraine. Ubrogepant is a small-molecule calcitonin gene-related peptide receptor antagonist. It is the first drug in this class approved for the acute treatment of migraine.

The most common side effects are nausea, tiredness and dry mouth. Ubrogepant is contraindicated for co-administration with strong CYP3A4 inhibitors.